ClearPoint Neuro, Inc. (CLPT)
NASDAQ: CLPT · Real-Time Price · USD
24.98
-2.34 (-8.57%)
At close: Oct 21, 2025, 4:00 PM EDT
25.69
+0.71 (2.85%)
After-hours: Oct 21, 2025, 7:12 PM EDT
ClearPoint Neuro Revenue
ClearPoint Neuro had revenue of $9.22M in the quarter ending June 30, 2025, with 17.27% growth. This brings the company's revenue in the last twelve months to $33.59M, up 19.68% year-over-year. In the year 2024, ClearPoint Neuro had annual revenue of $31.39M with 31.04% growth.
Revenue (ttm)
$33.59M
Revenue Growth
+19.68%
P/S Ratio
20.67
Revenue / Employee
$292,113
Employees
115
Market Cap
710.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.39M | 7.44M | 31.04% |
| Dec 31, 2023 | 23.96M | 3.40M | 16.56% |
| Dec 31, 2022 | 20.55M | 4.25M | 26.09% |
| Dec 31, 2021 | 16.30M | 3.47M | 27.05% |
| Dec 31, 2020 | 12.83M | 1.61M | 14.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CLPT News
- 14 days ago - ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles - Accesswire
- 15 days ago - ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide - Accesswire
- 19 days ago - ClearPoint Neuro: AMT-130 Highlights A Bright Future - Seeking Alpha
- 20 days ago - ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System - Accesswire
- 26 days ago - ClearPoint Neuro: Selling The Tools For Brain Therapies - Seeking Alpha
- 26 days ago - ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer - Accesswire
- 6 weeks ago - ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners - Accesswire
- 2 months ago - ClearPoint Neuro: Biopharma Momentum Continues To Build - Seeking Alpha